Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic...

Area of Science:

• Cardiology
• Neurology
• Clinical Trials

Background:

• Patients with acute coronary syndromes (ACS) and a history of stroke or transient ischemic attack (TIA) experience elevated risks of recurrent cardiac events and intracranial hemorrhages.
• This high-risk population requires careful consideration for antithrombotic therapy.

Purpose of the Study:

• To evaluate the treatment effects of ticagrelor compared to clopidogrel in patients with ACS who have a history of prior stroke or TIA.
• To assess the efficacy and safety of ticagrelor in this specific high-risk subgroup within the PLATO trial.

Main Methods:

• Analysis of data from the PLATelet inhibition and patient Outcomes (PLATO) trial, which randomized 18,624 patients.
• Subgroup analysis of 1152 patients (6.2%) with a history of stroke or TIA, comparing ticagrelor to clopidogrel.
• Evaluation of primary composite outcomes, total mortality, and bleeding events, including intracranial bleeding.

Main Results:

• Patients with prior stroke or TIA had higher rates of myocardial infarction, death, stroke, and intracranial bleeding compared to those without.
• Ticagrelor demonstrated consistent efficacy in reducing the primary composite outcome and total mortality in patients with prior stroke/TIA, mirroring overall trial results.
• Overall and intracranial bleeding rates were similar between ticagrelor and clopidogrel in this high-risk group.

Conclusions:

• Patients with ACS and a history of ischemic stroke or TIA exhibit worse clinical outcomes.
• Ticagrelor's efficacy and bleeding profile in this high-risk population are consistent with the broader trial findings.
• Ticagrelor offers a favorable clinical net benefit and impacts mortality in ACS patients with a history of stroke or TIA.